Transition Therapeutics (TTHI) 5.59 $TTHI
Transition Therapeutics (TTHI) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:51AM CDT
Transition Therapeutics Inc. was a big mover last session, as its shares rose nearly 12% on the day.
Transition Therapeutics Announces No Material Change
PR Newswire - Tue Apr 15, 11:11AM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) reports today that there are no undisclosed material changes or corporate developments involving the Company to account for its recent change in stock price.
Transition Therapeutics Announces Development Update
CNW Group - Mon Apr 07, 5:30AM CDT
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI) (TSX: TTH) provided an update on the development of its drug candidates and plans for future growth. The addition of the neuropsychiatric drug candidate ELND005 has broadened the Company's development pipeline with an un-partnered late-stage clinical asset, coupled with Transition's core strategy of advancing assets acquired from pharmaceutical partners. From a corporate standpoint, the Company will seek to leverage the economic benefits of ELND005 and future in-licensed assets through its recently acquired Irish domiciled subsidiary, Transition Therapeutics Ireland Limited. The Company has completed a rigorous evaluation of each of its development programs with the intent to implement a balanced strategy for growth in three key areas: late stage development of ELND005 in neuropsychiatric indications, Phase 2 development of diabetes drug candidate TT401, and capacity for the addition of one or two new in-licensed programs. A conference call will be held on Monday, April 7, 2014 at 8:30am Eastern time to discuss the development update with investors.
Perrigo Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 5:30PM CDT
Perrigo inked a deal to manufacture store brand versions of nutritional drinks for adults.
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 27, 3:25PM CDT
Despite mixed signals from China's economy and a biotech swoon, it doesn't seem anything can put a dent into the side of the S&P 500 following its five-year-plus run. For skeptics like me, that's an opportunity to see whether companies have...
Perrigo Continues to Expand - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 11:50AM CST
Perrigo is constantly entering into acquisition and collaboration agreements to expand its business.
Transition Therapeutics to Present at the 34th Annual Cowen & Co. Healthcare Conference
CNW Group - Mon Mar 03, 12:15PM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI) (TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the 34(th) Annual Cowen & Co. Healthcare Conference on Tuesday, March 4th, 2014 at 10:00 a.m. Eastern Time at the Boston Marriott Copley Place Hotel in Boston, MA.
Transition Therapeutics (TTHI) Jumps: Stock Moves 7.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:46AM CST
Transition Therapeutics was a big mover last session, with shares rising nearly 8%.
Transition Therapeutics to progress development activities and costs associated with ELND005 (Scyllo-inositol)
M2 - Mon Mar 03, 5:56AM CST
Healthcare supplier Perrigo Company (NYSE
RGO)(NYSE:TASE) said on Friday that it has entered into a transition agreement for the clinical development of its ELND005 (Scyllo-inositol) in several important indications such as Alzheimer's disease, Bipolar Disorder and Down Syndrome.
Perrigo Company plc and Transition Therapeutics Modify Development and Commercialization Rights of ELND005 Program
CNW Group - Fri Feb 28, 6:25AM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) announced the acquisition of an Irish domiciled company ("Irish Subsidiary", the holder of all the development and commercialization rights of neuropsychiatric drug candidate, ELND005. The Company also announced a US$15 million investment by Perrigo to acquire approximately 7% of Transition's common shares. ELND005 is an oral drug candidate that is being evaluated in three studies: a Phase 2 study for Agitation and Aggression in Alzheimer's Disease, a Phase 2 study for Bipolar Disorder and a Phase 2A study in Down Syndrome.
Perrigo Company plc Announces The Transfer Of Development Asset ELND005 To Transition Therapeutics Inc.
PR Newswire - Fri Feb 28, 6:13AM CST
Perrigo Company plc (NYSE: PRGO; TASE) announced today that it entered into a series of agreements with existing collaboration partner, Transition Therapeutics Inc. (Nasdaq: TTHI), to progress the clinical development of ELND005 (Scyllo-inositol) in a number of important indications including Alzheimer's disease, Bipolar Disorder and Down Syndrome. As part of the transaction, Transition Therapeutics will acquire all of the shares of a wholly owned, indirect Irish subsidiary of Perrigo Company plc which has present day responsibilities for carrying out all development activities associated with ELND005. Additionally, affiliates of Perrigo Company plc will make a $15 million investment in return for 2,255,640 common shares of Transition Therapeutics and will be eligible to receive royalties and milestone payments should ELND005 be commercialized. As of closing today, Transition Therapeutics and its subsidiaries will become responsible for all ongoing development activities and costs associated with ELND005.
Transition Therapeutics Inc's net loss narrows to USD1.25m in Q2 fiscal 2014
M2 - Thu Feb 13, 3:21AM CST
Biopharmaceutical company Transition Therapeutics Inc (TSX:TTH.TO) (NasdaqGM:TTHI) stated on Wednesday its net loss of USD1.25m (USD0.04 loss per common share) for the three month period ended 31 December 2013.
Transition Therapeutics Announces Second Quarter Fiscal 2014 Financial Results
CNW Group - Wed Feb 12, 3:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (TSX: TTH) (NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the three and six month periods ended December 31, 2013.
Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2014 Financial Results on Wednesday, February 12th, at 4:30 P.M. EST
PR Newswire - Fri Feb 07, 12:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company" (NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, February 12th, 2014 at 4:30 P.M. EST to discuss Second Quarter Fiscal 2014 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call (800) 617-7643 (North America), (303) 223-2688 (International). A replay of the conference call will be available on Transition's website www.transitiontherapeutics.com for seven days following the call.
Transition Therapeutics (TTHI) Jumps: Stock Up 11.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:51AM CDT
Transition Therapeutics Inc. was a big mover last session, as its shares rose nearly 12% on the day.
Transition Therapeutics Announces No Material Change
PR Newswire - Tue Apr 15, 11:11AM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) reports today that there are no undisclosed material changes or corporate developments involving the Company to account for its recent change in stock price. Transition Therapeutics Announces Development Update
CNW Group - Mon Apr 07, 5:30AM CDT
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI) (TSX: TTH) provided an update on the development of its drug candidates and plans for future growth. The addition of the neuropsychiatric drug candidate ELND005 has broadened the Company's development pipeline with an un-partnered late-stage clinical asset, coupled with Transition's core strategy of advancing assets acquired from pharmaceutical partners. From a corporate standpoint, the Company will seek to leverage the economic benefits of ELND005 and future in-licensed assets through its recently acquired Irish domiciled subsidiary, Transition Therapeutics Ireland Limited. The Company has completed a rigorous evaluation of each of its development programs with the intent to implement a balanced strategy for growth in three key areas: late stage development of ELND005 in neuropsychiatric indications, Phase 2 development of diabetes drug candidate TT401, and capacity for the addition of one or two new in-licensed programs. A conference call will be held on Monday, April 7, 2014 at 8:30am Eastern time to discuss the development update with investors. Perrigo Inks Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 27, 5:30PM CDT
Perrigo inked a deal to manufacture store brand versions of nutritional drinks for adults.
3 Stocks Near 52-Week Highs Worth Selling
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 27, 3:25PM CDT
Despite mixed signals from China's economy and a biotech swoon, it doesn't seem anything can put a dent into the side of the S&P 500 following its five-year-plus run. For skeptics like me, that's an opportunity to see whether companies have...
Perrigo Continues to Expand - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 06, 11:50AM CST
Perrigo is constantly entering into acquisition and collaboration agreements to expand its business.
Transition Therapeutics to Present at the 34th Annual Cowen & Co. Healthcare Conference
CNW Group - Mon Mar 03, 12:15PM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI) (TSX: TTH) announced today that Dr. Tony Cruz, Chairman and Chief Executive Officer of Transition will be presenting at the 34(th) Annual Cowen & Co. Healthcare Conference on Tuesday, March 4th, 2014 at 10:00 a.m. Eastern Time at the Boston Marriott Copley Place Hotel in Boston, MA. Transition Therapeutics (TTHI) Jumps: Stock Moves 7.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Mar 03, 8:46AM CST
Transition Therapeutics was a big mover last session, with shares rising nearly 8%.
Transition Therapeutics to progress development activities and costs associated with ELND005 (Scyllo-inositol)
M2 - Mon Mar 03, 5:56AM CST
Healthcare supplier Perrigo Company (NYSE
RGO)(NYSE:TASE) said on Friday that it has entered into a transition agreement for the clinical development of its ELND005 (Scyllo-inositol) in several important indications such as Alzheimer's disease, Bipolar Disorder and Down Syndrome. Perrigo Company plc and Transition Therapeutics Modify Development and Commercialization Rights of ELND005 Program
CNW Group - Fri Feb 28, 6:25AM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) announced the acquisition of an Irish domiciled company ("Irish Subsidiary", the holder of all the development and commercialization rights of neuropsychiatric drug candidate, ELND005. The Company also announced a US$15 million investment by Perrigo to acquire approximately 7% of Transition's common shares. ELND005 is an oral drug candidate that is being evaluated in three studies: a Phase 2 study for Agitation and Aggression in Alzheimer's Disease, a Phase 2 study for Bipolar Disorder and a Phase 2A study in Down Syndrome. Perrigo Company plc Announces The Transfer Of Development Asset ELND005 To Transition Therapeutics Inc.
PR Newswire - Fri Feb 28, 6:13AM CST
Perrigo Company plc (NYSE: PRGO; TASE) announced today that it entered into a series of agreements with existing collaboration partner, Transition Therapeutics Inc. (Nasdaq: TTHI), to progress the clinical development of ELND005 (Scyllo-inositol) in a number of important indications including Alzheimer's disease, Bipolar Disorder and Down Syndrome. As part of the transaction, Transition Therapeutics will acquire all of the shares of a wholly owned, indirect Irish subsidiary of Perrigo Company plc which has present day responsibilities for carrying out all development activities associated with ELND005. Additionally, affiliates of Perrigo Company plc will make a $15 million investment in return for 2,255,640 common shares of Transition Therapeutics and will be eligible to receive royalties and milestone payments should ELND005 be commercialized. As of closing today, Transition Therapeutics and its subsidiaries will become responsible for all ongoing development activities and costs associated with ELND005.
Transition Therapeutics Inc's net loss narrows to USD1.25m in Q2 fiscal 2014
M2 - Thu Feb 13, 3:21AM CST
Biopharmaceutical company Transition Therapeutics Inc (TSX:TTH.TO) (NasdaqGM:TTHI) stated on Wednesday its net loss of USD1.25m (USD0.04 loss per common share) for the three month period ended 31 December 2013.
Transition Therapeutics Announces Second Quarter Fiscal 2014 Financial Results
CNW Group - Wed Feb 12, 3:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(TSX: TTH) (NASDAQ: TTHI), a product-focused biopharmaceutical company developing therapeutics for disease indications with large markets, today announced its financial results for the three and six month periods ended December 31, 2013. Transition Therapeutics to Hold Conference Call on Second Quarter Fiscal 2014 Financial Results on Wednesday, February 12th, at 4:30 P.M. EST
PR Newswire - Fri Feb 07, 12:01PM CST
Transition Therapeutics Inc. ("Transition" or the "Company"
(NASDAQ: TTHI, TSX: TTH) will hold a conference call on Wednesday, February 12th, 2014 at 4:30 P.M. EST to discuss Second Quarter Fiscal 2014 financial results. Dr. Tony Cruz, Chairman and Chief Executive Officer of the Company, will host the call. Transition will announce its financial results for this period in a press release to be issued prior to the call. In order to participate in the conference call, please call (800) 617-7643 (North America), (303) 223-2688 (International). A replay of the conference call will be available on Transition's website www.transitiontherapeutics.com for seven days following the call. 
